Qiagen raises FY25 adjusted EPS target to about $2.38, consensus $2.37

Qiagen (QGEN) reaffirmed its FY25 outlook for net sales growth of about 4-5% CER, or about 5-6% CER core sales excluding divestments, and raised its adjusted diluted EPS target to about $2.38 CER, from previously about $2.35 CER. Qiagen also expects an adjusted operating income margin of about 29.5%, or about 30% CER, in 2025 while absorbing headwinds from currency movements and tariffs. “Our strong profitability and cash generation are allowing QIAGEN to step up shareholder returns. With the execution of the $500 million repurchase in January 2026 that shareholders approved at our last Annual General Meeting, we are returning more than $1 billion to shareholders well ahead of our 2028 goal. We remain focused on generating the highest returns and are reviewing how to increase this target while also strengthening our portfolio through organic investments and targeted acquisitions such as Parse. We anticipate that our ongoing capital allocation decisions will bring our leverage ratio toward the industry average of about 2x in 2026,” said CFO Roland Sackers.